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of the drugs they were taking, most of the respondents 
were uninformed. In contrast to their more-than-adequate 
level of communication about their patients’ illnesses, most 
practitioners seemed to avoid counselling patients on the 
effects and side-effects of therapy. It is hoped that this study 
will increase awareness of the need for effective counselling on 
drug effects and side-effects.
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Iron deficiency anaemia in healthy South African women 
despite iron fortification
Denise Lawrie, Lindi Marie Coetzee, Deborah Kim Glencross
To the Editor: The prevalence of iron deficiency in a South 
African urban environment is probably in keeping with 
European and USA findings of around 10%. Although our 
results present the prevalence of iron deficiency anaemia 
among urban females, a more detailed study that includes 
ferritin levels is needed for confirmation. Awareness of and 
attention to screening for iron deficiency remain essential for 
improving the quality of life and productivity of women in 
South Africa.
Method and findings
We used data from a study on the prevalence of HIV infection 
among health care workers in South Africa,1 to evaluate and 
revalidate the current automated full blood count reference 
ranges for the Gauteng region. A striking finding was the large 
number of samples that had to be excluded from the statistical 
analysis because of the presence of anaemia.
Samples were obtained from 631 HIV-negative adult females 
working at the Helen Joseph and Coronation Hospitals in 
Gauteng. The demographics were representative of the urban 
population in South Africa.
The current National Health Laboratory Service (NHLS) full 
blood count reference range for adult females in the Gauteng 
region for haemoglobin (Hb) is 12.1 - 16.3 g/dl, haematocrit 
(HCT) 0.37 - 0.49 l/l, and mean cell volume (MCV) 79.1 - 98.9 
fl. Using these reference ranges, the criteria for possible iron 
deficiency were defined as a combined Hb level below 12 
g/dl, an HCT below 0.37 l/l, and an MCV of less than 79 fl. 
Approximately 10% of the 631 participants had microcytic 
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hypochromic red cell indices, which is in keeping with possible 
iron deficiency. One participant showed the macrocytic indices 
and thrombocytopenia associated with megaloblastic anaemia. 
Another had an elevated red cell count with microcytic 
hypochromic indices suggestive of a haemoglobinopathy. A 
further 5% had haemoglobin levels below 12 g/dl and HCTs 
<0.37 l/l, but normal MCV.
Of the subjects with possible iron deficiency (10% overall), 
19% were aged 20 - 30 years, 14% 40 - 50 years, 7.6% 30 - 40 
years and 7.5% >50 years. Few local data are available on the 
prevalence of anaemia in ‘normal’ non-pregnant urban women. 
A prevalence of 10% in non-pregnant coloured women was 
reported from the Cape Peninsula in 1994.2 Local studies on 
pregnant women reported a prevalence of iron deficiency 
anaemia (IDA) of 9 - 12% in 2000 that contributed to 7.3% of 
perinatal deaths and 4.9% of maternal deaths. An estimated 
0.4% of all deaths in South Africa in 2000 could be attributed to 
iron deficiency.3
Discussion
Our conservative estimate of the prevalence of anaemia among 
‘healthy’ South African adult females in Gauteng is 15%, with 
10% of females showing features suggestive of IDA. This 
probably underestimates the prevalence in South Africa, as the 
study was conducted among economically active, apparently 
healthy females in an urban environment.
IDA remains a global health care problem affecting an 
estimated 2 billion people, both in developing and First-World 
countries.4 The Global Burden of Disease project in 2000 
concluded that there was an urgent need to develop effective 
and sustainable interventions in the control of IDA. Europe 
and the USA introduced iron fortification of flour in 1998, and 
the prevalence of anaemia decreased from 30% to 10%. Food 
fortification was identified as a possible strategy for preventing 
iron deficiency in South Africa in 1975.5 Although opinions 
on fortification still vary,6 fortification of maize and wheat 
flour was legislated in South Africa in 2003. At the time, South 
Africa also received a US$2.8 million grant from the World 
Health Organization (WHO)-led Global Alliance for Improved 
Nutrition (GAIN) to support a food fortification programme 
for 3 years. Successful management of IDA has also been 
achieved through the UN World Food Program (WFP) by 
cereal fortification in Afghanistan, Angola and Zambia and bio-
fortification strategies in China.7,8 These efforts underline the 
importance of food fortification as an effective strategy against 
nutritional iron deficiency.
Although our figures for possible IDA were lower than those 
in Japan (22.3%), Israel (24%) and India (20%), their laboratory 
methods for assessing the condition were more detailed, and 
the population socio-demographics are different. In addition, 
it was assumed that most women in our study consumed iron-
fortified foodstuffs.
The laboratory infrastructure for screening and diagnosing 
anaemia is widely available throughout South Africa in 
the private and public sectors. The cost of basic screening 
(haemoglobin – Board of Healthcare Providers (BHF) rate 
R13.20) is low. However, most women only have their 
haemoglobin levels tested (and are incidentally diagnosed as 
having IDA) on admission to a hospital or antenatal clinic, 
or when donating blood. In South Africa, with the current 
prevalence of IDA and in the context of the high prevalence of 
HIV, clinicians and primary health care professionals should 
consider basic screening of haemoglobin more frequently. This 
could be extended further at the primary health care level by a 
basic ‘dipstick’ method.
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Oral fluid detection of hepatitis B vaccine-induced 
antibodies can improve vaccination programmes
Omphile E Simani, Guido François, Rosemary J Burnett, André Meheus, Herbert R Basetse, M Jeffrey Mphahlele
To the Editor: About 387 million people (over 5% of the global 
population) are chronically infected with the hepatitis B virus 
(HBV).1 The World Health Organization (WHO) plans to 
contain the burden of HBV infections by means of universal 
vaccination programmes for infants and adolescents. The 
vaccine may be almost universally available to children within 
the next few years.2 A major drawback of monitoring immunity 
to the hepatitis B vaccine or HBV infection is the need for a 
blood specimen to detect hepatitis B surface antibodies (anti-
HBs). Collecting blood is by needle, and is often painful and 
traumatic for babies, children and adults with poor venous 
access, so non-invasive sampling would be an ideal alternative.
Several oral fluid collection devices exist.3-7 The OraSure 
(OraSure Technologies Inc., USA), a non-invasive cotton pad 
impregnated with gelatine, salts (sodium chloride, citric acid, 
sodium benzoate, potassium sorbate, and sodium hydroxide 
to give pH 6.5) and deionised water is approved for use in 
humans by the USA’s Food and Drug Administration (FDA) 
and is licensed for collection of oral mucosal transudate 
(OMT) for anti-HIV testing.8 As OMT is a serous fluid rich 
in immunoglubulins (IgG, IgM and IgA), it is possible to 
test for antibodies induced by infections of public health 
importance such as hepatitis A virus (HAV), HBV, hepatitis C 
virus (HCV),7,9,10 human papillomavirus type 1611 and many 
others.6 Samples can also be used to investigate the presence of 
hepatitis B surface antigen.12
We aimed to assess the OraSure device for collection of 
OMT samples; modify a serum-based commercial enzyme-
linked immunosorbent assay (ELISA) kit (Murex anti-HBs 
ELISA, Murex Biotech Limited) for the detection of anti-HBs 
from OMT specimens; and evaluate the suitability of OMT as 
an alternative to blood for detecting anti-HBs induced by the 
hepatitis B vaccine.
Methods
A total of 67 paired serum and OMT specimens were collected 
from vaccinated health care workers (HCWs) at Dr George 
Mukhari Hospital, Medunsa complex. In addition, 5 HCWs 
previously identified as having undetectable anti-HBs despite 
hepatitis B vaccination were used as negative controls. An 
OMT sample and ≤3 ml of blood (using a 5 ml syringe and 
Vacutainer tubes) were collected after obtaining consent from 
each HCW. Blood samples were collected, processed and stored 
as previously described.13 To obtain OMT samples, the OraSure 
pad was placed for 2 minutes between the lower gum and 
inner cheek. The osmotic action of the pad draws antibodies 
from the mucosal tissues. Antibodies move from the capillaries 
to interstitial fluid and across the mucosa. The collection device 
is immediately placed into a preservative solution, where it 
remains stable for up to 21 days when stored at 20 - 37oC, or at 
room temperature. All serum specimens were tested for anti-
HBs with automated AUSAB IMx assay13 and manual Murex 
anti-HBs ELISA, following manufacturers’ instructions. The 
OMT specimens were tested only with Murex ELISA, after 
in-house experiments to modify and optimise the assay for 
detection of antibodies from oral fluid (results not shown).
Results
The AUSAB IMx assay (used as the gold standard) accurately 
determines anti-HBs to approximately 1 mIU/ml. Using this 
assay, the sera of 65 (97.0%) of 67 hepatitis B-vaccinated HCWs 
were found to be anti-HBs positive, and 2 (3.0%) were anti-
HBs negative (Table I). None of the 5 controls tested positive 
for anti-HBs with AUSAB IMx assay. Testing with the AUSAB 
IMx assay therefore identified 65 seropositive for anti-HBs, 
and 7 negatives. The 65 anti-HBs positives had anti-HBs titres 
ranging from 1.2 to >1 000 mIU/ml.
The anti-HBs results from the AUSAB IMx assay were 
compared with those obtained from the serum samples tested 
with Murex anti-HBs ELISA (Table IA). The Murex assay 
detected anti-HBs in 64 (98.5%) of the 65 positive sera, and 
in none of the 7 negative sera, leading to one false negative 
(the anti-HBs titre of this sample was 1.2 mIU/ml, which was 
below the cut-off value (≥5 mIU/ml) for the Murex assay). The 
Murex assay therefore yielded a sensitivity of 98.5% (i.e. 64/65) 
and specificity of 100% (i.e. 7/7).
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The anti-HBs results from the AUSAB IMx assay were 
compared with the Murex ELISA on OMT samples. All 67 OMT 
specimens from vaccinated HCWs were reactive for anti-HBs 
using the Murex assay, including the 2 identified as anti-HBs 
negative by the AUSAB IMx assay. Therefore, the OMT-based 
testing resulted in 2 false positives (Table IB). However, all 
5 OMT specimens from the control group were non-reactive 
for anti-HBs. The Murex assay on OMT samples showed a 
sensitivity of 100% and specificity of 71.4%.
Discussion
In keeping with previous reports,5,10 we demonstrated that anti-
HBs can be detected from oral fluid. The quality of sampling 
is not affected by common oral pathologies, recent food intake, 
cigarette smoke, dentures, drugs causing dry mouth, or HIV 
status.14 Although different oral fluid collection devices are 
commercially available,3-6 a limitation is that most assays for 
detection of antibodies are optimised and licensed for use with 
blood or serum samples. Further investigations are needed 
to optimise the sensitivity and specificity of these assays to 
accurately detect and quantitatively measure antibodies from 
oral fluid samples. Oral diagnostic testing of antibodies is 
particularly attractive for epidemiological and surveillance 
studies in developing countries, and has been used to 
determine antibody status for rubella in Ethiopian children15,16 
and antibodies to diphtheria-tetanus-pertussis (DTP) in 
British children,6 and can monitor hepatitis B immunisation 
programmes in babies or adolescents, as most developing 
countries are now introducing hepatitis B vaccine into their 
national immunisation programmes. Technologies such as oral 
diagnostic testing can enable developing countries to introduce 
new and under-utilised vaccines and monitor their impact with 
ease.
This study was supported in part by grants from the National 
Research Foundation and the Poliomyelitis Research Foundation 
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Table I. Detection of anti-HBs from serum and OMT samples and assay validation results using the AUSAB IMx as gold 
standard assay
      Positive          Negative     Total            Sens   Spec         PPV              NPV
A: AUSAB IMx sera v. Murex sera assay
Positive         64               0        64
Negative            1               7          8             98.5     100          100                87.5
Total          65               7        72   
B: AUSAB IMx sera v. Murex OMT assay
Positive         65               2        67
Negative           0               5          5              100    71.4          97.0                 100
Total          65               7        72    
Sens = sensitivity (true positive/true positive + false negative); Spec = specificity (true negative/true negative + false positive); PPV = positive predictive value (true positive/true 
positive + false positive); NPV = negative predictive value (true negative/true negative + false negative).
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